46 results
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
6 Aug 24
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
4:10pm
.
GAAP research and development (R&D) expenses were $29.1 million for the quarter ended June 30, 2024, as compared to $18.0 million for the quarter
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
8 May 24
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
earned from marketable securities.
GAAP research and development (R&D) expenses were $29.9 million for the quarter ended March 31, 2024, as compared
8-K
EX-99.1
tbuatc len43
11 Mar 24
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
4:05pm
424B5
zfg6b jl9971a
5 Jan 24
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
l77s7 hq6qjkg02
7 Nov 23
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
af962 1yt
5 Sep 23
Olema Oncology Announces Combined Financing for Up to $180 Million
7:39am
8-K
izfbg7680c8tn
5 Sep 23
Olema Oncology Announces Combined Financing for Up to $180 Million
7:39am
8-K
EX-99.1
39s01sc
8 Aug 23
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
yo2hqr7h
9 May 23
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm